This study compared treatment strategies for a defined endocrine condition. It was not a general study of hormone supplementation in healthy men. Primary study
What was studied
Thirty men with congenital hypogonadotropic hypogonadism entered an open-label randomized pilot comparing lower-dose hCG plus FSH and testosterone with a higher-dose hCG/FSH strategy. The report found no statistically significant difference in achieving spermatogenesis. Numerical inconsistencies in the indexed abstract require reconciliation before reproducing group percentages or selected biomarker summaries. Primary report
Our appraisal: a pilot cannot prove equivalence by failing to find a difference
When a small study reports a nonsignificant group comparison, the treatments may still differ meaningfully. An equivalence or noninferiority claim requires a prespecified margin, suitable design and confidence interval supporting that margin. A conventional P value does not supply those elements.
The intervention also changes more than one factor. hCG exposure, testosterone administration and titration targets form a treatment strategy rather than an isolated ingredient test. A result should therefore be attributed to the regimen as studied, not to one component or a simplified commercial combination.
Spermatogenesis is distinct from pregnancy and live birth. Detecting sperm may be an important milestone, but fertility outcomes depend on additional factors and longer observation. Hormonal biomarkers can help describe the process without automatically becoming validated substitutes for semen assessment or eventual reproductive outcomes.
The numerical presentation issue is a reason to withhold affected figures, not to guess the intended values. Full-report verification should also reconcile participant flow, time-to-event methods, prior hormone exposure and harms. Until then, this record can describe the study question and its limitations without providing a treatment algorithm or asserting that the regimens are interchangeable.
Frequently asked questions
Was this a healthy-volunteer supplementation trial?
No; participants had congenital hypogonadotropic hypogonadism.
Was the trial blinded?
It was described as open-label.
Was only hCG changed?
No; the strategies differed in multiple respects.
Does nonsignificance prove equivalence?
No.
Is spermatogenesis the same as live birth?
No.
Why are group percentages omitted?
The indexed numerical presentation needs verification.
Is this a self-treatment protocol?
No.